Klausen K P, Parving H-H, Scharling H, Jensen J S
Copenhagen City Heart Study, Epidemiological Research Unit, Bispebjerg University Hospital, Copenhagen, Denmark.
J Intern Med. 2007 Oct;262(4):470-8. doi: 10.1111/j.1365-2796.2007.01839.x.
Microalbuminuria and metabolic syndrome are both associated with cardiovascular disease (CVD). The aim of this study was to determine the potential association between numbers of components in the metabolic syndrome, different levels of microalbuminuria and renal function. We also aimed to determine the risk of death and CVD at different levels of microalbuminuria and renal function and numbers of components in the metabolic syndrome.
Population-based observational follow-up study.
Epidemiological research unit (Copenhagen City Heart Study).
A total of 2,696 men and women, 30-70 years of age. BASELINE MEASURES: Urinary albumin excretion (UAE), creatinine clearance and metabolic risk factors were measured in 1992-1994.
The participants were followed prospectively by registers until 1999-2000 with respect to CVD, and until 2004 with respect to death.
We found a strong association between microalbuminuria and the metabolic syndrome: 2% with none and 18% with five metabolic risk factors had microalbuminuria (P < 0.001). No association between impaired renal function defined as creatinine clearance <60 mL min(-1) and the metabolic syndrome was found. Microalbuminuria was associated with increased risk of death and CVD to a similar extend as the metabolic syndrome, irrespective of concomitant presence of metabolic syndrome (RR approximately 2; P < 0.001). Impaired renal function was not associated with increased risk of death and CVD in subjects with the metabolic syndrome.
Microalbuminuria (UAE >5 microg min(-1)) confers increased risk of death and CVD to a similar extent as the metabolic syndrome.
微量白蛋白尿和代谢综合征均与心血管疾病(CVD)相关。本研究的目的是确定代谢综合征各组分数量、不同水平的微量白蛋白尿与肾功能之间的潜在关联。我们还旨在确定不同水平的微量白蛋白尿、肾功能以及代谢综合征各组分数量时的死亡和CVD风险。
基于人群的观察性随访研究。
流行病学研究单位(哥本哈根市心脏研究)。
共2696名年龄在30 - 70岁之间的男性和女性。
在1992 - 1994年测量尿白蛋白排泄量(UAE)、肌酐清除率和代谢危险因素。
通过登记系统对参与者进行前瞻性随访,直至1999 - 2000年观察心血管疾病情况,直至2004年观察死亡情况。
我们发现微量白蛋白尿与代谢综合征之间存在强关联:无代谢危险因素者中2%有微量白蛋白尿,有5个代谢危险因素者中18%有微量白蛋白尿(P < 0.001)。未发现定义为肌酐清除率<60 mL·min⁻¹的肾功能受损与代谢综合征之间存在关联。微量白蛋白尿与死亡和CVD风险增加的关联程度与代谢综合征相似,无论是否伴有代谢综合征(相对危险度约为2;P < 0.001)。在患有代谢综合征的受试者中,肾功能受损与死亡和CVD风险增加无关。
微量白蛋白尿(UAE>5μg·min⁻¹)与代谢综合征一样,会使死亡和CVD风险增加到相似程度。